Isolation of the various serotypes of Mannheimia haemolytica and preparation of the first vaccine candidate in Iran.

Hajar Molaee, Yahya Tahamtan, Ehlam Saeednezhad, Masoumeh Hayati

Abstract read

In one paragraph

Article in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Immune Cells in the Spleen of Mice Mediate the Inflammatory Response Induced byAnimals : an open access journal from MDPI · 2024
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hajar MolaeeImmunology Department, Shiraz Branch, Agricultural Research, Razi Vaccine and Serum Research Institute, Education and Extension Organization (AREEO), Shiraz, Iran.

Yahya TahamtanMicrobiology Department, Shiraz Branch, Agricultural Research, Razi Vaccine and Serum Research Institute, Education and Extension Organization (AREEO), Shiraz, Iran. yahyatahamtan@yahoo.com.ORCID http://orcid.org/0000-0002-6566-4081

Ehlam SaeednezhadDepartment of Microbiology Shiraz Branch, Islamic Azad University, Shiraz, Iran.

Masoumeh HayatiMolecullar Biology Department, Shiraz Branch, Agricultural Research, Razi Vaccine and Serum Research Institute, Education and Extension Organization (AREEO), Shiraz, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMannheimia haemolytica is one of the main agents of domestic pneumonic mannheimiosis, but a proper vaccine has not been explored in IRAN. METHODS AND

results362 lung and nasal samples from sick domestic animal were detected by culture and PCR methods. Totally, 71 M. haemolytica isolates were identified in three main serotypes (A1, A2, and A6). Serotypes A2 (38/71; 54%) and A1 (25/71; 39%) were the most frequently detected, whereas the A6 serotype was detected with a frequency of less than 1% (1/71; 1%) and 7 isolates remained unknown (7/71; 10%). Subsequently, M. haemolytica vaccinal strain was developed and then formalin-killed vaccine was prepared. It provided the best protection against mannheimiosis in sheep which was proved by indirect ELISA.

conclusionsOur results suggest that the efficacy and safety of vaccine strain are remarkable and may serve as a new therapeutic target in mannheimiosis.

Indexed as

Mannheimia haemolyticaSheep DiseasesAnimalsBacterial VaccinesIranSerogroupSheepBacterial VaccinesAntibodyMannheimia haemolyticaSerotypeVaccine strain

Identifiers

PMID36097127

DOI10.1007/s11033-022-07890-4

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.